The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy

Canadian Journal of Gastroenterology

Volumn 24, Issue 8, 2010, Pages 481-488

  Superceanu, Bogdan ^a   Van Zanten, Sander Veldhuyzen ^b   Skedgel, Chris ^a   Shepherd, Michael ^a   Sketris, Ingrid ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cohort study; Cyclooxygenase 2 selective inhibitor; Drug utilization; Gastrointestinal prophylaxis; Histamine 2 receptor antagonist; Misoprostol; Nonsteroidal anti inflammatory drugs; NSAIDs; Prescribing; Proton pump inhibitor; Seniors

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETODOLAC; FAMOTIDINE; FENOPROFEN; FLOCTAFENIC ACID; FLURBIPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; MELOXICAM; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PROTON PUMP INHIBITOR; SALSALATE; SULINDAC; TENOXICAM; TIAPROFENIC ACID; TOLMETIN;

AGED; ARTICLE; CANADA; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DRUG USE; DUODENUM ULCER; ELDERLY CARE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; STOMACH PROTECTION; STOMACH ULCER; TREATMENT DURATION; TREND STUDY;

EID: 77956810683     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/397610     Document Type: Article

References (32)

1. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72. (Erratum in 1994;343:1048).
2. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
3. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
4. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8. (Erratum in 1994;343:1302).
5. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin, non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8.
6. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Non-steroidal anti inflammatory drugs and the incidence of hospitalization for peptic ulcer disease in elderly persons. Am J Epidemiology 1995;141:539-45.
7. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non steroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
8. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12.
9. Hunt RH, Barkun AN, Baron D, et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of coxibs: Defining the role of gastroprotective agents. Can J Gastroenterol 2002;16:231-40.
10. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
11. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99. (Erratum in 1999;341:548).
12. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;4:CD002296.
13. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997;112:1817-22.
14. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine. Brit Med J 1988;297:1017-21.
15. Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003;42(Suppl 3):23-31.
16. Hartnell N, Flanagan P, MacKinnon N, Bakowsky V. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada. Am J Geriatr Pharmacother 2004;2:171-80.
17. Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005;129:1171-8.
18. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001;52:185-92.
19. Bakowsky VS, Hanly JG. Complications of nonsteroidal anti-inflammatory drug gastropathy and use of gastric cytoprotection: Experience at a tertiary care health center. J Rheumatol 1999;26:1557-63.
20. Grootendorst P. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: History and assessment. Can J Clin Pharmacol 2002;9:79-99.
21. Sketris IS, Nagpal S, O'Brien B, Kephart G, Wheeler-Usher D, Grace E. Proton pump inhibitor use in Nova Scotia seniors under pharmacare's reimbursement guidelines. Canadian Association of Population Therapeutics. Banff, March 31 to April 3. Can J Clin Pharmacol 2001;8:23.
22. NICE. Osteoarthritis and rheumatoid arthritis - Cox II inhibitors. 〈http://www.nice.org.uk/page.aspx?o=18033〉 (Accessed on October 25, 2008).
23. Moens HJ, van Croonenborg JJ, van den Bemt PMLA, Lourens J, Numans ME. Richtlijn NSAID-gebruik en preventie van maagschade [Dutch Institute of Healthcare Improvement CBO. Guideline: NSAID use and prevention of gastric injury.] Nederlands tijdschrift voor geneeskunde 2004;148:604-8. 〈http://www.cbo.nl/product/richtlijnen/folder20021023121843/richtlijnnsaid. pdf/view〉 (Accessed on November 26, 2008).
24. Chan FK, Graham DY. Review article: Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004;19:1051-61.
25. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15.
26. Langman M, Kong SX, Zhang Q, Kahler KH, Finch E. Safety and patient tolerance of standard and slow-release formulations of NSAIDs. Pharmacoepidemiol Drug Saf 2003;12:61-6.
27. van Dijk KN, ter Huurne K, de Vries CS, van den Berg PB, Brouwers JR, de Jong-van den Berg LT. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci 2002;24:100-3.
28. Rahme E, Marentette MA, Kong SX, Lelorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002;47:595-602.
29. Schnitzer TJ, Kong SX, Mavros PP, Straus WL, Watson DJ. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: Analysis of a large United States claims database. Clin Ther 2001;23:1984-98.
30. Zacny J, Sketris I, Skedgel C, Kephart G, Veldhuyzen van Zanten SJO. Utilization of antisecretory medication in 100,000 Nova Scotia Seniors' pharmacare beneficiaries between 1998 and 2002: A cohort database analysis. Gastroenterology 2004;126(Suppl 2):W1277, A-603.
31. Lanas A, Fereandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 2007;24:121-31.
32. Mamdani M, Warren L, Kopp A, et al. Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario. CMAJ 2006;175:1535-8.